Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Primary immunodeficiency disorders

M. Louise Markert – Primary immunodeficiency disorders

Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia A Prospective Monocentric Study to Assess the Concordance of Lung MRI Compared to Chest CT Scan to Assess the Extent and Severity of Bronchial and Parenchymal Pulmonary Lesions in Adult Patients With Primary Immune Deficiency (PID) . TCR Alpha/Beta and CD19 TCD in HCT for Patients With Hematological Malignancies and Nonmalignant Disorders An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) Primary Immunodeficiencies in Costa Rican Adults An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts Primitive Immunodeficiency and Pregnancy A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency COVID-19 in PID Survey Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death Retrospective Chart Review of Subcutaneous IgG Use in Infants Ig NextGen 10% in Patients With Primary Immune Deficiency (PID) TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children Investigation of Immune Disorders and Deficiencies Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases NIAID Centralized Sequencing Protocol Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment Study of Gut Microbiota in Primary Immune Deficiency, Possibly Associated With Inflammatory Bowel Disease Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA) Severe Immune Cytopenia Registry Www.Sic-reg.Org Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) Intensive Care Unit and Secondary and Primary Immune Deficiency Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml Identification of New Inborn Errors of Immunity Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency CD34+ Stem Cell Infusion to Augment Graft Function Octagam 5% Versus Comparator Post Marketing Trial Bilateral Orthotopic Lung Transplant – Bone Marrow Transplant Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency Subcutaneous Ig NextGen 16% in PID Patients Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During Childhood Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) Evaluation of the Efficacy of the Sequencing Method by Gene-panel Pathophysiology of Inborn Immunodeficiencies Study of Octanorm Subcutaneous IG in Patients With PID TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Immunological Characteristics of Patients With PID and IBD Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study) Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) Evaluation of Efficacy and Tolerability of Hizentra® Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study) Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam) Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)? Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency Pediatric Primary Immunodeficiency Disease (PID) in China IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases Study to Monitor the Safety, Tolerability and Efficacy of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases, Including (But Not Limited to) Those Who Have Completed the SCGAM-01 Trial Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) ASIS for GAMMAGARD in Primary Immunodeficiency Minipooled-IVIG in Primary Immunodeficiency Disease Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care. A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products Primary Immunodeficiency in Kuwait Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI) Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations